Assessing the Prognostic Value of the Automated Bone Scan Index for Prostate Cancer-Reply

Andrew J Armstrong¹, Orjan Nordle², Michael Morris^{3

4}

Affiliations

¹ Department of Medicine, Department of Surgery, Department of Pharmacology and Cancer Biology, Duke Cancer Institute Divisions of Medical Oncology and Urology Duke University, Durham, North Carolina.
² Nordle Biostatistical Consultancy, Rydebäck, Sweden.
³ Memorial Sloan Kettering Cancer Center, New York, New York.
⁴ Weill Cornell Medicine, New York, New York.

Comment

Andrew J Armstrong et al. JAMA Oncol. 2019.

. 2019 Feb 1;5(2):270-271.

doi: 10.1001/jamaoncol.2018.5874.

Andrew J Armstrong¹, Orjan Nordle², Michael Morris^{3

4}

¹ Department of Medicine, Department of Surgery, Department of Pharmacology and Cancer Biology, Duke Cancer Institute Divisions of Medical Oncology and Urology Duke University, Durham, North Carolina.
² Nordle Biostatistical Consultancy, Rydebäck, Sweden.
³ Memorial Sloan Kettering Cancer Center, New York, New York.
⁴ Weill Cornell Medicine, New York, New York.

No abstract available

Comment on

Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Armstrong AJ, Anand A, Edenbrandt L, Bondesson E, Bjartell A, Widmark A, Sternberg CN, Pili R, Tuvesson H, Nordle Ö, Carducci MA, Morris MJ. Armstrong AJ, et al. JAMA Oncol. 2018 Jul 1;4(7):944-951. doi: 10.1001/jamaoncol.2018.1093. JAMA Oncol. 2018. PMID: 29799999 Free PMC article. Clinical Trial.
Assessing the Prognostic Value of the Automated Bone Scan Index for Prostate Cancer.
Sun R, Zhu H, Wei LJ. Sun R, et al. JAMA Oncol. 2019 Feb 1;5(2):270. doi: 10.1001/jamaoncol.2018.5857. JAMA Oncol. 2019. PMID: 30543368 No abstract available.